Vesalius Longevity Labs Inc.
About Vesalius Longevity Labs Inc.
Vesalius Longevity Labs is a peptide and longevity company building the first publicly traded platform dedicated to physician-prescribed peptide therapeutics. It operates a scalable B2Doctor2Consumer ecosystem supporting healthcare providers, telehealth infrastructure, product fulfillment, and advanced longevity therapeutics. The company offers injectables, patches, nasal sprays, oral, and topical formulations primarily U.S.-sourced. It maintains a global distribution network across North America, Europe, UAE, Asia Pacific, and Latin America.
- 🔗 Vesalius Longevity Labs Inc.
- 🔗 Vesalius Longevity Labs - 2026 Company Profile & Competitors - Tracxn
- 🔗 Vesalius Longevity Labs
- 🔗 Wisp and Vesalius Longevity Labs Partner to Launch Peptide Therapeutics Designed to Address Women’s Health Needs
- 🔗 Wisp & Vesalius Forge Women-Centric Longevity Path With Peptide Therapy Launch
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Announced strategic partnership with Wisp to launch peptide therapeutics for women’s health needs.
- Operates global B2Doctor distribution model serving independent licensed healthcare providers.
- Maintains presence on CSE:VLAB as a publicly traded longevity science platform.
- Focuses on regulatory-forward peptide therapeutics with products including injectables and topical formulations.
Ask StreetZero about Vesalius Longevity Labs Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account